Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Baptiste Abbar

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Acta Oncologica (Stockholm, Sweden)|June 5, 2023
FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective studyCyril Roussel-Simonin, Paul Gougis, Donia Lassoued, et al.
The Oncologist|December 26, 2024
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancerCamille Mehlman, Aurelie Swalduz, Isabelle Monnet, et al.
JAMA Network Open|April 17, 2024
Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and NewbornsPaul Gougis, Anne-Sophie Hamy, Floriane Jochum, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2022
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinomaLucie Meynard, Derek Dinart, Blandine Delaunay, et al.
Frontiers in Immunology|January 6, 2023
Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cellsMarianne Gazzano, Christophe Parizot, Dimitri Psimaras, et al.
Journal for Immunotherapy of Cancer|August 23, 2024
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort studyLambert Assoumou, Raghiatou Baldé, Christine Katlama, et al.
Cancer Immunology, Immunotherapy : CII|May 24, 2026
Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad studyKarim Amrane, Luca Campedel, Fabien Moinard-Butot, et al.
Cells|March 25, 2022
Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and CancerMarine Baron, Cathia Soulié, Armelle Lavolé, et al.
The Lancet Regional Health. Europe|February 3, 2025
Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort studyLotta Plomp, Hortense Chassepot, Dimitri Psimaras, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 9, 2025
Human Immunodeficiency Virus Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in NSCLCBaptiste Abbar, Karim Labreche, Jacques Cadranel, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Acta Oncologica (Stockholm, Sweden)|June 5, 2023
FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective studyCyril Roussel-Simonin, Paul Gougis, Donia Lassoued, et al.
The Oncologist|December 26, 2024
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancerCamille Mehlman, Aurelie Swalduz, Isabelle Monnet, et al.
JAMA Network Open|April 17, 2024
Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and NewbornsPaul Gougis, Anne-Sophie Hamy, Floriane Jochum, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2022
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinomaLucie Meynard, Derek Dinart, Blandine Delaunay, et al.
Frontiers in Immunology|January 6, 2023
Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cellsMarianne Gazzano, Christophe Parizot, Dimitri Psimaras, et al.
Journal for Immunotherapy of Cancer|August 23, 2024
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort studyLambert Assoumou, Raghiatou Baldé, Christine Katlama, et al.
Cancer Immunology, Immunotherapy : CII|May 24, 2026
Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad studyKarim Amrane, Luca Campedel, Fabien Moinard-Butot, et al.
Cells|March 25, 2022
Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and CancerMarine Baron, Cathia Soulié, Armelle Lavolé, et al.
The Lancet Regional Health. Europe|February 3, 2025
Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort studyLotta Plomp, Hortense Chassepot, Dimitri Psimaras, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 9, 2025
Human Immunodeficiency Virus Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in NSCLCBaptiste Abbar, Karim Labreche, Jacques Cadranel, et al.
Pageof 4